Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 30, 2021 - Issue 4: Biliary tract cancers.
Submit an article Journal homepage
1,843
Views
5
CrossRef citations to date
0
Altmetric
Editorial

The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs

Qurat Ul Ain Riaz Sipraa Department of Medicine, University of Arizona, Tucson, AZ, USAView further author information
&
Rachna Shroffb Department of Medicine, Division of Hematology/Oncology, University of Arizona, Tucson, AZ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0066-2672View further author information
ORCID Icon
Pages 281-284 | Received 19 Sep 2020, Accepted 04 Nov 2020, Published online: 23 Nov 2020

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico & Giovanni Brandi. (2021) FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert Review of Gastroenterology & Hepatology 15:5, pages 567-574.
Read now
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2021) Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opinion on Investigational Drugs 30:4, pages 343-350.
Read now

Articles from other publishers (3)

Alessandro Rizzo. (2021) Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina 57:5, pages 458.
Crossref
Alessandro Rizzo & Giovanni Brandi. (2021) Novel Targeted Therapies for Advanced Cholangiocarcinoma. Medicina 57:3, pages 212.
Crossref
Stephen P. Hack, Wendy Verret, Sohail Mulla, Bo Liu, Yulei Wang, Teresa Macarulla, Zhenggang Ren, Anthony B. El-Khoueiry & Andrew X. Zhu. (2021) IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592110365.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.